Scarica l'app Stockscreener
4.28
4.04%
-0.18
Onkure Therapeutics Inc Borsa (OKUR) Ultime notizie
ETFs Investing in OnKure Therapeutics, Inc. Class A Stocks - TradingView
Enterprise value to EBITDA forward of OnKure Therapeutics, Inc. – NASDAQ:OKUR - TradingView
OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026 - The Manila Times
OnKure lines up July 15 virtual event on cancer-drug design - Stock Titan
OnKure Therapeutics, Inc.(NasdaqGM: OKUR) added to Russell 2000 Index - marketscreener.com
OnKure Therapeutics, Inc.(NasdaqGM:OKUR) added to Russell Small Cap Completeness Index - marketscreener.com
OnKure Therapeutics, Inc.(NasdaqGM:OKUR) added to Russell Small Cap Comp Value Benchmark - marketscreener.com
OnKure Therapeutics, Inc. Class A Actuals & Estimates (NASDAQ:OKUR) - TradingView
OKUR Forecast — Price Target — Prediction for 2027 - TradingView
Analysts Offer Insights on Healthcare Companies: OnKure Therapeutics (OKUR) and CalciMedica (CALC) - The Globe and Mail
OnKure Therapeutics president and CEO sells $378 in stock By Investing.com - Investing.com Nigeria
OnKure Therapeutics president and CEO sells $378 in stock - Investing.com
OnKure Therapeutics CFO Jason Leverone sells $1,332 in stock - Investing.com
Form 4 Onkure Therapeutics Inc For: 24 June By Investing.com - Investing.com Nigeria
OnKure Therapeutics CFO Jason Leverone sells $1,332 in stock By Investing.com - Investing.com Nigeria
[Form 4] OnKure Therapeutics, Inc. Insider Trading Activity - Stock Titan
OnKure Therapeutics (OKUR) CFO auto-sells shares to cover RSU tax withholding - Stock Titan
Onkure Therapeutics Inc (OKUR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Onkure Therapeutics Inc (OKUR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Onkure Therapeutics Inc (OKUR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Onkure Therapeutics Inc (OKUR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Onkure Therapeutics Inc (OKUR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Onkure Therapeutics Inc (OKUR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Onkure Therapeutics Inc (OKUR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Onkure Therapeutics Inc (OKUR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
OKUR Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances Pipeline - newsline.com
Onkure Therapeutics Inc (OKUR) Institutional Confidence - TradingKey
OnKure Therapeutics Sees Volatile Trading Amid Recent Developments - timothysykes.com
OKUR Q1 2026 Earnings: EPS Miss by 46.55% Signals Aggressive Pipeline InvestmentEarnings Revision Upgrade - newsline.com
OKUR SEC FilingsOnKure Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
OnKure Therapeutics Inc. (OKUR) Q1 2026 Earnings: Wider-than-Expected Loss as Stock Edges HigherWeak Earnings Momentum - dars.gov.et
OnKure Therapeutics (OKUR) director receives 7,650 stock options grant - Stock Titan
OnKure Therapeutics (OKUR) director awarded 1,275 stock options at $4.30 strike - Stock Titan
Director at OnKure (NASDAQ: OKUR) receives 7,650 stock options - Stock Titan
OnKure (OKUR) awards director 7,650 stock options at $4.30 - Stock Titan
OnKure (OKUR) director receives 7,650 options at $4.30 strike - Stock Titan
OnKure (OKUR) director awarded 7,650 stock options at $4.30 strike - Stock Titan
Onkure Therapeutics patents new PI3Kα mutant inhibitors - BioWorld News
OKUR Q1 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue StageSlow Growth Warning - newsline.com
OnKure Shareholders Approve Amended 2024 Equity Incentive Plan - The Globe and Mail
OnKure Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
OnKure (NASDAQ: OKUR) holders back equity plan changes and board slate - Stock Titan
OnKure Therapeutics (OKUR) Holds Steady Near Support: Can $4.43 Resistance Be Breached?Breakout Confirmation - newsline.com
OKUR Q1 2026 Earnings: EPS Miss of 46.6% Highlights Early-Stage R&D CostsGuidance Upgrade Report - thelegaladvocate.com
OnKure Therapeutics (OKUR) Advances 2.55% as Stock Holds Above Key SupportBollinger Expansion - The Legal Advocate
OKUR Q1 2026 Earnings: Wider EPS Loss Underscores Heavy R&D Investment as Pre-Revenue Biotech Advances PipelineEarnings Surprise Stocks - newsline.com
[SCHEDULE 13G] OnKure Therapeutics, Inc. Passive Investment Disclosure (>5%) - Stock Titan
OKUR Q1 2026 Earnings: Wider-than-Expected Loss Reflects R&D InvestmentEarnings Stability Report - The Legal Advocate
OKUROnKure Therapeutics Inc Stock Price and Quote - Finviz
OnKure Therapeutics Inc. (OKUR) Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances PipelineMargin Guidance - The Legal Advocate
Survey finds most Boulder residents satisfied with quality of life - BizWest
OnKure Therapeutics (OKUR) Surges 14% Amid Renewed Investor InterestMerger Arbitrage - Newser
OnKure Therapeutics (OKUR) Q1 2026 Earnings Miss: EPS $-1.11 vs $-0.76 ExpectedReal Trader Insights - Newser
OnKure Therapeutics (OKUR) Jumps +7.88% on Strong Momentum 2026-05-20Technical Analysis Picks - The Legal Advocate
ADAR1 entities and Daniel Schneeberger report 6.0% of OnKure (NASDAQ: OKUR) - Stock Titan
TradingKey - TradingKey
The long term thesis for OnKure Therapeutics (OKUR) in plain sight (Breakdown Watch) 2026-05-11Social Momentum Signals - newser.com
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):